Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Olema Pharmaceuticals Inc (OLMA)

Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 301,737
  • Shares Outstanding, K 68,421
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,470 K
  • EBIT $ -143 M
  • EBITDA $ -142 M
  • 60-Month Beta 1.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.80

Options Overview Details

View History
  • Implied Volatility 164.35% ( +4.51%)
  • Historical Volatility 63.63%
  • IV Percentile 53%
  • IV Rank 17.70%
  • IV High 773.50% on 04/04/25
  • IV Low 33.34% on 09/12/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 1,473
  • Open Int (30-Day) 1,528

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.43
  • Number of Estimates 6
  • High Estimate -0.35
  • Low Estimate -0.70
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +20.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.02 +9.70%
on 06/23/25
5.01 -11.98%
on 07/09/25
+0.31 (+7.56%)
since 06/18/25
3-Month
3.89 +13.37%
on 06/13/25
5.74 -23.10%
on 05/02/25
-0.01 (-0.23%)
since 04/17/25
52-Week
2.86 +54.20%
on 04/07/25
16.62 -73.47%
on 08/01/24
-10.04 (-69.48%)
since 07/18/24

Most Recent Stories

More News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMA : 4.41 (-2.22%)
Investors Bet on Biotech as Public Cancer Research Hits a Wall

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – As cancer rates continue to climb worldwide, the race to develop better, faster, and more affordable treatments...

ONCY : 1.2700 (-3.79%)
AGEN : 6.15 (-8.48%)
OLMA : 4.41 (-2.22%)
ICCM : 1.0200 (+0.99%)
ONC.TO : 1.73 (-2.81%)
ATNM : 1.7100 (+5.56%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMA : 4.41 (-2.22%)
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

OLMA : 4.41 (-2.22%)
Olema Oncology to Participate in Upcoming Investor Conferences

OLMA : 4.41 (-2.22%)
Olema Oncology Reports First Quarter 2025 Financial and Operating Results

OLMA : 4.41 (-2.22%)
Olema Oncology to Participate in Upcoming Investor Conferences

OLMA : 4.41 (-2.22%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMA : 4.41 (-2.22%)
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

OLMA : 4.41 (-2.22%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMA : 4.41 (-2.22%)

Business Summary

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California....

See More

Key Turning Points

3rd Resistance Point 4.96
2nd Resistance Point 4.84
1st Resistance Point 4.62
Last Price 4.41
1st Support Level 4.28
2nd Support Level 4.16
3rd Support Level 3.94

See More

52-Week High 16.62
Fibonacci 61.8% 11.36
Fibonacci 50% 9.74
Fibonacci 38.2% 8.12
Last Price 4.41
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar